CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer, AKB-4924. AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease (IBD). “Unlike other HIF stabilizers that mainly affect HIF-2 and stimulate erythropoiesi
Author: Business Wire
Tear Film Innovations Completes $8.5 Million Series B Funding
SAN DIEGO–(BUSINESS WIRE)–Tear Film Innovations completes $8.5 million Series B Preferred Stock funding round led by Visionary Ventures Fund, L.P. and Bluestem Capital.
PanOptica Doses First Patient with New Formulation of PAN-90806, a Novel, Topical Anti-VEGF Eye Drop, in Phase 1/2 Clinical Trial
BERNARDSVILLE, N.J.–(BUSINESS WIRE)–PanOptica announced that it has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806
Objective Acuity Has World’s Pre-Schoolers in Its Sights
AUCKLAND, New Zealand–(BUSINESS WIRE)–Objective Acuity’s innovative vision screening test for children reduces incorrect referrals to eye specialists. Its screen test takes a few seconds.
GenSight Biologics tiendra une présentation investisseurs à New York le 12 juin 2018
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (Paris: SIGHT), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce aujourd’hui qu’une présentation investisseurs se tiendra le 12 juin 2018 à New York, de 8h00 à 10h30 (heure locale). Le management, ainsi que des leaders d’opin
GenSight Biologics to Host KOL Event on June 12, 2018
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it will host a KOL Event on June 12, 2018 in New York City from 8 a.m. – 10:30 a.m. ET. Management and Key Opinion Leaders in the gene therapy and ophthalmology space will present full r
Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD
LARKSPUR, Calif.–(BUSINESS WIRE)–Vitrisa Therapeutics, Inc., a Company focused on developing a suite of platform technologies optimized for ocular therapeutics and an associated pipeline of therapeutics in sight-threatening ocular diseases, today announced that it has entered into an option agreement with Ohr Pharmaceutical for certain rights to the data from the MAKO study in wet-AMD (“wAMD”). Under the terms of the newly announced deal, Vitrisa will initially receive non-exclusive rights to
Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients With Neovascular (wet) AMD
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–ICONIC starts second Phase 2 study
With New CEO at Helm, eyebobs Expands into Brick & Mortar Retail with Two Locations Opening Summer of 2018
MINNEAPOLIS–(BUSINESS WIRE)–eyebobs, a Minneapolis-based eyewear brand for the irreverent and slightly jaded, is proud to announce its plans to smash through the traditional eyewear retail model with the launch of two brick and mortar locations opening in the summer of 2018. The brand’s expansion is led by CEO Mike Hollenstein, who brought a wealth of previous retail experience to drive eyebobs’ 2017 launch of its prescription eyewear offerings and is now helping the brand break the mold of t
Aerpio Pharmaceuticals Announces Nomination of Industry Veteran Cheryl Cohen to Board of Directors
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced the nomination of a new director, Cheryl Cohen, to its Board of Directors. Ms. Cohen will stand for election at Aerpio’s 2018 Annual Meeting of Stockholders on June 20, 2018. If approved, Ms. Cohen will bring to Aerpio more than 25 years of experience in the biopharmaceutical industry, with a focus on strategic pr
Global Contact Lens Market 2018-2022 – Key Players are Johnson & Johnson, Novartis, The Cooper Companies, Valeant Pharmaceuticals, and Zeiss – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Contact Lens Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The global contact lens market is projected to grow at a CAGR of 6.45% during the period 2018-2022. The report has been prep…
SeniorWell Hires New Chief Technology Officer
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare company, today announced the hiring of John Clifford as Chief Technology Officer.
New Drug-eluting Contact Lens to Provide Timed Drug Delivery Directly to Eye; Improving Recovery, Reducing Cost for Millions after Eye Surgery and LASIK
MULLICA HILL, N.J.–(BUSINESS WIRE)–New Drug-eluting Contact Lens to Provide Drug Delivery Directly to Eye; Improving Recovery, Reducing Cost for Millions after Eye Surgery and LASIK
PatientPop Survey Reveals Majority of Healthcare Providers Don’t Know How to Affect Online Reputation
SANTA MONICA, Calif.–(BUSINESS WIRE)–#healthcare–PatientPop, the leader in practice growth technology, today released its 2018 Healthcare Providers Survey Report: Online Reputation Management. The nationwide survey of medical and dental professional…
Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the first quarter ended March 31, 2018. Stephen Hoffman, M.D. Ph.D., Chief Executive Officer of Aerpio, commented, “We are pleased that TIME-2b, our ongoing Phase 2b study in patients with non-proliferative diabetic retinopathy (NPDR), is fully enrolled ahead of schedule. This study will evalu
Telescope Implant for End-State Macular Degeneration Now on the Federal Supply Schedule and Available at Department of Veteran’s Affairs Hospitals Across the Country Via MellingMedical
SARATOGA, Calif.–(BUSINESS WIRE)–#centrasight–Telescope Implant for AMD Now on the Federal Supply Schedule and Available at Department of Veteran’s Affairs Hospitals Across the Country Via Melling
Second Sight Medical Products, Inc. to Present at the 19th Annual B. Riley FBR Investor Conference
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision…
Global Glass Lens Market – Availability of Products Through Online Distribution Channels Promotes Growth| Technavio
LONDON–(BUSINESS WIRE)–#GlassLens–The latest report by Technavio on the global glass lens market estimate the market to grow at a CAGR of approximately 4% during the period 2018-2022.
Contact Lens Market – New and Improved Product Offerings by Manufacturers to Drive Growth | Technavio
LONDON–(BUSINESS WIRE)–#ContactLens–Technavio market research analysts forecast the global contact lens market to grow at a CAGR of above 6% during the period 2018-2022.
Global Retinal Drugs Market 2018-2022: Market to Grow at a CAGR of 7.63% – Key Vendors are Allergan, Bayer, F. Hoffmann-La Roche, Novartis, Regeneron & Valeant – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Retinal Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The global retinal drugs market to grow at a CAGR of 7.63% during the period 2018-2022. Global Retinal Drugs Market 2018-20…